Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can lower drug doses make stem cell transplants safer for seniors?

NCT ID NCT05849207

Recruiting now Disease control Sponsor: Ronald Paquette Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This study is for people aged 65 and older with blood cancers who are getting a stem cell transplant. Researchers want to see if giving a lower dose of the drug cyclophosphamide after the transplant can reduce serious side effects while still controlling the cancer. The trial will test four different dose levels in a small group of 26 participants to find the safest and most effective dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cyclophosphamide
What this could lead to
If successful, this could help older patients receive stem cell transplants with fewer severe side effects, making the treatment safer and more tolerable.
What could go wrong
This is a very early phase 1 trial with only 26 participants, so results may not apply broadly. Lowering the dose might increase the risk of graft-versus-host disease or transplant failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.